KPMG Video Insights information@kpmg.de https://videostream.kpmg.de de-de Visualplatform http://blogs.law.harvard.edu/tech/rss KPMG Video Insights Unser Podcast für Interessierte Banking episodic no https://videostream.kpmg.de/files/rv1.36/sitelogo.gif https://videostream.kpmg.de http://videostream.kpmg.de/trends-and-challenges-for-life <p><p>Life sciences companies have maneuvered quite well through the Covid-19 pandemic. In the new reality it will be relevant, that the companies leverage their increased societal importance to develop innovative drugs at affordable prices and to become more customer-oriented. Thomas Hillek, Head of Life Sciences &amp; Chemicals at KPMG in Germany, explains which four overarching trends influence the new reality of life sciences companies and highlights possible actions.</p></p><p><a href="http://videostream.kpmg.de/trends-and-challenges-for-life"><img src="http://videostream.kpmg.de/60445029/64802367/4a1a6d7c46b2d76b1dd8558b9795d795/standard/download-16-thumbnail.jpg" width="75" height=""/></a></p> http://videostream.kpmg.de/photo/64802367 Tue, 05 Jan 2021 17:38:10 GMT Trends and challenges for life sciences companies in the new reality Life sciences companies have maneuvered quite well through the Covid-19 pandemic. In the new reality it will be relevant, that the companies leverage their increased societal importance to develop innovative drugs at affordable prices and to become more customer-oriented. Thomas Hillek, Head of Life Sciences Chemicals at KPMG in Germany, explains which four overarching trends influence the new reality of life sciences companies and highlights possible actions. Life sciences companies have maneuvered quite well through the Covid-19 pandemic. In the new reality it will be relevant, that the companies leverage their increased societal importance to develop innovative drugs at affordable prices and to... KPMG Video Insights 02:42 <p><p>Life sciences companies have maneuvered quite well through the Covid-19 pandemic. In the new reality it will be relevant, that the companies leverage their increased societal importance to develop innovative drugs at affordable prices and to become more customer-oriented. Thomas Hillek, Head of Life Sciences &amp; Chemicals at KPMG in Germany, explains which four overarching trends influence the new reality of life sciences companies and highlights possible actions.</p></p><p><a href="http://videostream.kpmg.de/trends-and-challenges-for-life"><img src="http://videostream.kpmg.de/60445029/64802367/4a1a6d7c46b2d76b1dd8558b9795d795/standard/download-16-thumbnail.jpg" width="75" height=""/></a></p> agility artificial intelligence collaboration models connected enterprise Covid-19 customer experience digitalization english enterprise models health life science companies life sciences medicine new reality patient patient centricity pharmacenticals R&D research supply chain technology therapy transformation http://videostream.kpmg.de/ma-markt-und-1 <p>Der globale M&amp;A-Markt hatte während der Covid-19-Pandemie einen deutlichen Rückgang zu verzeichnen. Das hat sich auch bei den Transaktionen in der Life-Sciences-Branche bemerkbar gemacht. Unser Experte Christian Klingbeil geht davon aus, dass sich der Transaktionsmarkt aber recht schnell erholen wird – erste&nbsp;Zukäufe sind schon wieder zu beobachten. Wie&nbsp;die Transaktionsstrategie der Life-Sciences-Unternehmen in der neuen Normalität aussieht,&nbsp;erläutert er in diesem Video.&nbsp;&nbsp;</p><p><a href="http://videostream.kpmg.de/ma-markt-und-1"><img src="http://videostream.kpmg.de/60445190/64747351/33e3eb88f9772c0b4aed91d9a83ecfe4/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://videostream.kpmg.de/photo/64747351 Tue, 05 Jan 2021 17:09:10 GMT M&A-Markt und Life-Sciences-Unternehmen: Transaktionen in der neuen Normalität Der globale MA-Markt hatte während der Covid-19-Pandemie einen deutlichen Rückgang zu verzeichnen. Das hat sich auch bei den Transaktionen in der Life-Sciences-Branche bemerkbar gemacht. Unser Experte Christian Klingbeil geht davon aus, dass sich der Transaktionsmarkt aber recht schnell erholen wird – ersteZukäufe sind schon wieder zu beobachten. Wiedie Transaktionsstrategie der Life-Sciences-Unternehmen in der neuen Normalität aussieht,erläutert er in diesem Video. Der globale MA-Markt hatte während der Covid-19-Pandemie einen deutlichen Rückgang zu verzeichnen. Das hat sich auch bei den Transaktionen in der Life-Sciences-Branche bemerkbar gemacht. Unser Experte Christian Klingbeil geht davon aus, dass sich... KPMG Video Insights 02:09 <p>Der globale M&amp;A-Markt hatte während der Covid-19-Pandemie einen deutlichen Rückgang zu verzeichnen. Das hat sich auch bei den Transaktionen in der Life-Sciences-Branche bemerkbar gemacht. Unser Experte Christian Klingbeil geht davon aus, dass sich der Transaktionsmarkt aber recht schnell erholen wird – erste&nbsp;Zukäufe sind schon wieder zu beobachten. Wie&nbsp;die Transaktionsstrategie der Life-Sciences-Unternehmen in der neuen Normalität aussieht,&nbsp;erläutert er in diesem Video.&nbsp;&nbsp;</p><p><a href="http://videostream.kpmg.de/ma-markt-und-1"><img src="http://videostream.kpmg.de/60445190/64747351/33e3eb88f9772c0b4aed91d9a83ecfe4/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> Akquisitionsstrategie Covid-19 Digitalisierung Innobation Krise Life-Sciences-Unternehmen M&A-Markt Pharmaunternehmen Portfolio Private-Equity-Unternehmen R&D strategische Allianzen Technologie Transaktionen Zukäufe http://videostream.kpmg.de/ma-market-and-life-sciences <p><p>The global M&amp;A market declined significantly during the Covid-19 pandemic. This has also been reflected in&nbsp;transactions in the life sciences sector. However, our expert Christian Klingbeil assumes that the transaction market will recover quite quickly – first acquisitions can already be observed&nbsp;again. In this video, he explains how the transaction strategy of life sciences companies looks like in the new reality.</p></p><p><a href="http://videostream.kpmg.de/ma-market-and-life-sciences"><img src="http://videostream.kpmg.de/60445026/64747724/67ac0ff7aeecd5a45e933ea9d5a04f09/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> http://videostream.kpmg.de/photo/64747724 Tue, 05 Jan 2021 16:57:56 GMT M&A market and life sciences companies: transactions in the new reality The global MA market declined significantly during the Covid-19 pandemic. This has also been reflected intransactions in the life sciences sector. However, our expert Christian Klingbeil assumes that the transaction market will recover quite quickly – first acquisitions can already be observedagain. In this video, he explains how the transaction strategy of life sciences companies looks like in the new reality. The global MA market declined significantly during the Covid-19 pandemic. This has also been reflected intransactions in the life sciences sector. However, our expert Christian Klingbeil assumes that the transaction market will recover quite... KPMG Video Insights 02:07 <p><p>The global M&amp;A market declined significantly during the Covid-19 pandemic. This has also been reflected in&nbsp;transactions in the life sciences sector. However, our expert Christian Klingbeil assumes that the transaction market will recover quite quickly – first acquisitions can already be observed&nbsp;again. In this video, he explains how the transaction strategy of life sciences companies looks like in the new reality.</p></p><p><a href="http://videostream.kpmg.de/ma-market-and-life-sciences"><img src="http://videostream.kpmg.de/60445026/64747724/67ac0ff7aeecd5a45e933ea9d5a04f09/standard/download-12-thumbnail.jpg" width="75" height=""/></a></p> aquisitions bolt-on aquisitions corporation crisis digitalization english growth driven transactions innovation Life science companies M&A market private equity R&D strategic alliances supply chain transactions transaction strategy